Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoblituzumab in pediatric B7-H3-expressing solid tumors
NCT02982941Phase 1Completed
- Sponsor
- MacroGenics
- Start
- Dec 2016
- Primary completion
- May 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enoblituzumab in neuroblastoma, rhabdomyosarcoma (RMS), osteosarcoma (OS) and 4 more, sponsored by MacroGenics. Primary endpoint: Safety and tolerability of enoblituzumab up to 2 years. Started Dec 2016; status: completed.
02
Drugs
enoblituzumab
03
Conditions
neuroblastomarhabdomyosarcoma (RMS)osteosarcoma (OS)Ewing sarcomaWilms' tumor
Beyond the preview
Go deeper on NCT02982941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982941.